Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

M. Jackman, David; Y. Yeap, Beow; V. Sequist, Lecia; Lindeman, Neal; J. Holmes, Alison; A. Joshi, Victoria; W. Bell, Daphne; S. Huberman, Mark; Halmos, Balazs; S. Rabin, Michael; A. Haber, Daniel; J. Lynch, Thomas; Meyerson, Matthew; E. Johnson, Bruce; A. Jänne, Pasi

doi:10.1158/1078-0432.ccr-06-0462

Public

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Shared by NobleBlocks on Jul 1, 2006 • 12:00 AM UTC

Authors:

David M. Jackman

Beow Y. Yeap

Lecia V. Sequist

Abstract

Abstract Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non–small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib. Our study explored the relationship between the two most common type...

Discussions